We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Remote Ischemic Conditioning to Attenuate Myocardial Death and Improve Operative Outcome. (RICARDO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03363958
Recruitment Status : Recruiting
First Posted : December 6, 2017
Last Update Posted : December 6, 2017
Sponsor:
Information provided by (Responsible Party):

November 30, 2017
December 6, 2017
December 6, 2017
January 1, 2014
January 1, 2019   (Final data collection date for primary outcome measure)
  • Postoperative myocardial necrosis [ Time Frame: 72 hours postoperatively ]
    Serial mesurements of High - Sensitive Troponin T release
  • Postoperative kidney injury [ Time Frame: 7 days postoperatively ]
    Serial measurements of estimated glomerular filtration rate by creatinine
Same as current
No Changes Posted
  • Perioperative mortality [ Time Frame: 30 days postoperatively ]
    30-day all cause mortality
  • Perioperative myocardial infarction [ Time Frame: 30 days postoperatively ]
    30-day myocardial infarction
  • Postoperative Acute Kidney Injury [ Time Frame: 30 days ]
    Prevalence of acute kidney injury according to Society of Thoracic Surgeons definitions of outcomes.
Same as current
Not Provided
Not Provided
 
Remote Ischemic Conditioning to Attenuate Myocardial Death and Improve Operative Outcome.
Effect of Remote Ischemic Conditioning on Ischemia and Reperfusion Injury in Patients Submitted to Coronary Artery Bypass Grafting.
This study evaluates the addition of remote ischemic preconditioning and postconditioning to standard myocardial protection protocol in patients submitted to off - pump coronary artery bypass grafting in a prospective, 1:1 randomized, double blind fashion. An interventional group will receive remote ischemic preconditioning 24-hours before OP-CABG, immediately before surgery and within 60 minutes following surgery by means of lower limb ischemia achieved by pressure cuff inflation, whereas control group will receive sham procedure perioperatively.

In a prospective, 1:1 randomized and double blind fashion, the study will evaluate the impact of remote ischemic preconditioning, both immediate and second window of protection (24 hours and immediately before surgery) with remote ischemic postconditiong on operative outcomes in patients submitted to coronary artery bypass grafting without use of extracorporeal circulation.

Remote ischemic conditioning was found to provide protection against necrosis and apoptosis due to ischemia and reperfusion injury, a phenomenon observed during coronary artery bypass grafting. That in turn was associated with poor postoperative outcomes, predominantly poor survival.

Remote ischemic preconditioning will be provided by repeated lower leg ischemia and reperfusion with pressure cuff inflation for five minutes and deflation for five minutes in three consecutive cycles. Remote ischemic preconditioning will be performed 24 hours before CABG and immediately before surgery. Remote ischemic postconditioning will be performed within 60 minutes following the last coronary artery bypass graft completion and the restoration of coronary blood flow.

The study will assess clinical endpoints such as postoperative acute myocardial infarction (type 5 MI), postoperative mortality, postoperative renal failure and laboratory outcomes such as postoperative serial measurements of troponin T release or glomerular filtration rate as secondary outcomes.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
  • Coronary Artery Bypass
  • Myocardial Reperfusion Injur
  • Ischemic Preconditioning, Myocardial
  • Ischemic Postconditioning
  • Procedure: Remote Ischemic Preconditioning with Postconditioning
    Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
  • Procedure: Sham RIPC procedure
    Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
  • Experimental: RIC Group
    Three cycles of remote ischemic conditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation); First three cycles the patient will receive 24 hours preoperatively, second three cycles the patient will receive after the induction of general anesthesia but before skin incision shortly before CABG. Remote ischemic postconditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation) will be administered to the patient within 60 minutes after the completion of all coronary artery bypass grafts and the restoration of coronary blood flow.
    Intervention: Procedure: Remote Ischemic Preconditioning with Postconditioning
  • Sham Comparator: Control Group
    Control group will receive sham procedure near identical to intervention. That will be afforded by inflation of pressure cuff on artificial leg hidden under the draping by an assistant who is not included in the research team and does not have any connection to study design and data analysis.
    Intervention: Procedure: Sham RIPC procedure
Marczak J, Nowicki R, Kulbacka J, Saczko J. Is remote ischaemic preconditioning of benefit to patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg. 2012 May;14(5):634-9. doi: 10.1093/icvts/ivr123. Epub 2012 Jan 26. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
January 1, 2020
January 1, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients qualified to coronary artery bypass grafting according to ESC/EACTS Guidelines of myocardial revascularization, suffering from:

  • Multivessel coronary artery disease amenable for surgical treatment
  • Negative history of previous cardiac or vascular surgery in childhood and afterwards.
  • Negative history of active neoplastic disease, neither past medical history of oncological treatment
  • Patients with non insulin dependent diabetes mellitus treated chronically with oral derivatives of sulfonylourea such as but not limited to: glibenclamide.

Exclusion Criteria:

Patients suffering from acute insuficiency of any organ/ system and those suffering from end stage organ failure such as:

  • Chronic renal disease - KDOQI stage ≥ 3;
  • Chronic renal failure class A by Child - Pugh'a;
  • Chronic respiratory failure (type I and II according to Campbell et al. and type I according to Wood et al.);
  • Chronic intermittent claudication class 2A according to Fontaine;
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact: Jakub S. Marczak, M.D. 0048883774566 marczak@space.pl
Contact: Sleiman S. Aboul - Hassan, M.D. 0048683882194 s.aboulhassan@gmail.com
Poland
 
 
NCT03363958
RIPC Trial
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Medinet Heart Centre
Medinet Heart Centre
Not Provided
Principal Investigator: Jakub S. Marczak, M.D. Medinet Heart Center
Medinet Heart Centre
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP